Everolimus
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9535 publications
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
Journal: Future oncology (London, England)
Published: October 31, 2026
Thrombotic Risk of Targeted Therapies in Breast Cancer: A Real-World Cohort Study.
Journal: Research square
Published: October 25, 2026
Therapeutic Drug Monitoring of Immunosuppressants in Cardiac Transplantation: Current Strategies, Evidence Gaps, and Future Directions.
Journal: Clinics in laboratory medicine
Published: October 22, 2026
Synchronous Bilateral Clear Cell Renal Cell Carcinoma With Multifocal Recurrence and Prolonged Disease Control Under Sequential Multimodal Therapy: A Case Report.
Journal: Archivos espanoles de urologia
Published: October 15, 2026
Beyond Crohn's disease: ileal Kaposi sarcoma in a transplant recipient presenting with subocclusive symptoms. A concomitant diagnosis of Crohn's disease and ileal Kaposi sarcoma.
Journal: Minerva gastroenterology
Published: October 07, 2026
Statement of Retraction: Everolimus ameliorates Helicobacter pylori infection-induced inflammation in gastric epithelial cells.
Journal: Bioengineered
Published: October 01, 2026
Giredestrant plus Everolimus in Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: September 30, 2026
STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.
Journal: Future oncology (London, England)
Published: September 28, 2026
Everolimus for Tinnitus: A Questionable Causal Chain [Letter].
Journal: Drug design, development and therapy
Published: September 25, 2026
Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.
Journal: Current opinion in oncology
Published: September 18, 2026
Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study.
Journal: Journal of clinical medicine
Published: September 12, 2026
Last Updated: 11/08/2026